clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention He Jiankui, the most common co-covered peer. The 7 average consequence score is above the beat benchmark of 5.7 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Xinhua Hospital
clinical-trial is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention He Jiankui, the most common co-covered peer. The 7 average consequence score is above the beat benchmark of 5.7 in the same window. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. We currently track 1 Biotech story that mention Xinhua Hospital, all published on August 1, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Xinhua Hospital. Shared-story counts are live from our verified record — not editorial picks.
Shanghai Jiaotong University launches investigation
The university forms a working group to comprehensively investigate the clinical trial and the associated Nature paper.
Joint investigation report published
Science magazine and Retraction Watch release findings detailing the undisclosed death and ethical lapses, bringing the case to public attention.
Fatal gene-editing trial conducted
A young girl receives an experimental gene-editing treatment for a developmental-delay-linked genetic defect at Xinhua Hospital; she later dies, an outcome the ethics board deems treatment-related.
He Jiankui gene-edited babies scandal breaks
Chinese scientist He Jiankui announces the birth of the world’s first gene-edited babies, triggering global outrage and prompting China to tighten research regulations.
A young girl's death in an undisclosed gene-editing trial, funded by $860,000 from her parents, has triggered an investigation at Shanghai Jiaotong University. The case exposes critical ethics gaps in China's surging biopharma sector and raises alarms for investors, partners, and regulators worldwide.